The Centers for Disease Control and Prevention said Friday that Moderna Inc.’s MRNA,
The COVID-19 vaccine produces an allergic reaction in a small percentage of people, similar to the agency’s findings on the coronavirus vaccine developed by BioNTech SE BNTX,
and Pfizer Inc. PFE,
Shares of Moderna rose 1.6% in pre-market trading on Monday. According to the CDC report, there were 10 cases of anaphylaxis among the approximately 4 million doses administered between December 21 and January 10. Both vaccines are mRNA-based vaccines, with similar efficacy rates in clinical trials. They are the only two COVID-19 vaccines authorized in the U.S. so far during the pandemic. The CDC previously recommended that health care providers prepare for the possibility of anaphylaxis among some people who get vaccinated. Shares of Moderna have risen 520.3% in the last twelve months, while the S&P 500 SPX,
increases by 15.6%.